Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients

Da Hea Seo, Yongin Cho, Sujin Lee, Seho Park, Seung Il Kim, Byeong Woo Park, Yumie Rhee

Research output: Contribution to journalArticle

Abstract

Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs. Methods: A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients without AIs use (group 2). Serum total cholesterol, high density lipoprotein cholesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque were assessed. Results: The baseline characteristics were similar between two groups and there was no significant difference in carotid IMT irrespective of AIs administration. However, ultrasonographic evaluation of carotid artery revealed that the presence of plaque in AI users was significantly higher than in non-AI users (66.7% vs. 41.9%, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes was also the significant risk factor for the plaque formation. Conclusions: There was no significant difference in lipid profile itself between two groups, but more importantly the presence of the plaque was much higher indicating possible detrimental effect of AI on cardiovascular system.

Original languageEnglish
Pages (from-to)579-587
Number of pages9
JournalKorean Journal of Internal Medicine
Volume34
Issue number3
DOIs
Publication statusPublished - 2019 May

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Carotid Intima-Media Thickness
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Cardiovascular System
Carotid Arteries
HDL Cholesterol
Blood Glucose
Fasting
Estrogens
Triglycerides
Cardiovascular Diseases
Odds Ratio
Cholesterol
Placebos

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{09ed8cd73bbb4700b5c636a92283c0c5,
title = "Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients",
abstract = "Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs. Methods: A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients without AIs use (group 2). Serum total cholesterol, high density lipoprotein cholesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque were assessed. Results: The baseline characteristics were similar between two groups and there was no significant difference in carotid IMT irrespective of AIs administration. However, ultrasonographic evaluation of carotid artery revealed that the presence of plaque in AI users was significantly higher than in non-AI users (66.7{\%} vs. 41.9{\%}, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes was also the significant risk factor for the plaque formation. Conclusions: There was no significant difference in lipid profile itself between two groups, but more importantly the presence of the plaque was much higher indicating possible detrimental effect of AI on cardiovascular system.",
author = "Seo, {Da Hea} and Yongin Cho and Sujin Lee and Seho Park and Kim, {Seung Il} and Park, {Byeong Woo} and Yumie Rhee",
year = "2019",
month = "5",
doi = "10.3904/kjim.2016.205",
language = "English",
volume = "34",
pages = "579--587",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "3",

}

Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients. / Seo, Da Hea; Cho, Yongin; Lee, Sujin; Park, Seho; Kim, Seung Il; Park, Byeong Woo; Rhee, Yumie.

In: Korean Journal of Internal Medicine, Vol. 34, No. 3, 05.2019, p. 579-587.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients

AU - Seo, Da Hea

AU - Cho, Yongin

AU - Lee, Sujin

AU - Park, Seho

AU - Kim, Seung Il

AU - Park, Byeong Woo

AU - Rhee, Yumie

PY - 2019/5

Y1 - 2019/5

N2 - Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs. Methods: A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients without AIs use (group 2). Serum total cholesterol, high density lipoprotein cholesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque were assessed. Results: The baseline characteristics were similar between two groups and there was no significant difference in carotid IMT irrespective of AIs administration. However, ultrasonographic evaluation of carotid artery revealed that the presence of plaque in AI users was significantly higher than in non-AI users (66.7% vs. 41.9%, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes was also the significant risk factor for the plaque formation. Conclusions: There was no significant difference in lipid profile itself between two groups, but more importantly the presence of the plaque was much higher indicating possible detrimental effect of AI on cardiovascular system.

AB - Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have shown controversial results. The aim of this study was to investigate lipid profiles, measurement of carotid intima-media thickness (IMT) and the presence of plaque among endocrine-responsive breast cancer treated with AIs compared to ones that were not treated with AIs. Methods: A total of 85 postmenopausal women, who underwent breast cancer surgery during the age of 50 to 64 without history of statin use were included. There were 42 patients who were treated with AIs over 1 year (group 1) and 43 patients without AIs use (group 2). Serum total cholesterol, high density lipoprotein cholesterol, triglycerides, fasting blood glucose, carotid IMT, and presence of plaque were assessed. Results: The baseline characteristics were similar between two groups and there was no significant difference in carotid IMT irrespective of AIs administration. However, ultrasonographic evaluation of carotid artery revealed that the presence of plaque in AI users was significantly higher than in non-AI users (66.7% vs. 41.9%, p = 0.02; odds ratio, 4.21 in adjusted model; p = 0.01). History of diabetes was also the significant risk factor for the plaque formation. Conclusions: There was no significant difference in lipid profile itself between two groups, but more importantly the presence of the plaque was much higher indicating possible detrimental effect of AI on cardiovascular system.

UR - http://www.scopus.com/inward/record.url?scp=85065573048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065573048&partnerID=8YFLogxK

U2 - 10.3904/kjim.2016.205

DO - 10.3904/kjim.2016.205

M3 - Article

C2 - 28838227

AN - SCOPUS:85065573048

VL - 34

SP - 579

EP - 587

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 3

ER -